Byondis appoints Timo van den Berg as Senior Director, R&D in Immuno-Oncology
NIJMEGEN, Netherlands, July 15, 2021 / PRNewswire / – Byondis BV today announced the appointment of Timo K. van den Berg, Ph.D., as Senior Director, Research and Development in Immuno-Oncology (IO). Van den berg will assume this role on September 1st, operating from the Byondis headquarters in Nijmegen.
In his new role, Van den berg will help shape Byondis’ IO pipeline, which includes the anti-SIRPα monoclonal antibody BYON4228.
“We are delighted to welcome Timo to the Byondis family. He is a globally recognized OI pioneer, having made important contributions in the field, such as being the first to describe the role of SIRPα and to recognize the potential of using this target to develop a drug for the benefit of patients with SIRPα. cancer ”, declared the scientific director of Byondis Wim dokter, Ph.D.
As a long-time collaborator of Byondis, the professor van den Berg played a central role in the discovery of the CD47-SIRPα axis as an innate immune checkpoint. CD47 is known in the IO space as the “don’t eat me” signal that allows tumors to escape recognition and destruction.
“I am very excited about this new chapter in my career,” said the professor. van den Berg. “I think Byondis and I are a good match. We share the same values, including a strong, goal-oriented work ethic, and a passion for improving the lives of patients by creating precision medications targeting patients. cancers that are difficult to treat. ”
Van den berg brings to Byondis over 30 years of experience in the field of IOs – as a renowned researcher, educator, inventor, speaker and co-author of over 175 peer-reviewed publications. His most recent position was Head and Principal Investigator, Immunotherapy Laboratory, Department of Molecular Hematology at Sanquin Research, Amsterdam, netherlands. Since 2017, Van den berg was Professor of Immunotherapy at Vrije Universiteit, which is affiliated with the Department of Molecular Cell Biology and Immunology at the University of Amsterdam Medical Center. He spent 25 years as research group leader and department head at the University Medical Center Amsterdam and at Sanquin Research. Sanquin, a non-profit organization responsible for the blood supply of the Netherlands, also develops and manufactures pharmaceuticals, conducts scientific research, and develops and performs diagnostic services.
Van den berg is a member of numerous boards, including the Amsterdam Infection and Immunity Institute and the Cancer Center Amsterdam. Its professional memberships include the Dutch Society for Immunology and the European Society for Clinical Investigation. He got his doctorate. of that of Amsterdam Vrije Universiteit, and his M.Sc. in Biological Sciences (cum laude) from the University of Amsterdam.
Determined to improve the lives of patients, Byondis is an independent, private clinical-stage biopharmaceutical company that creates innovative precision drugs targeting incurable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, its duocarmazine linker-drug (LD) technology, and ByonShieLD®, its conjugation technology site-specific, to generate the next generation of antibody-drug conjugates (ADCs).
Byondis’ broad development portfolio includes preclinical clinical programs as well as early and late stage clinical programs including anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985), from which the pivotal phase III study TULIP® recently published positive results. The company has a dedicated team of around 400 employees, including highly trained scientists and skilled technicians working in state-of-the-art R&D and good manufacturing practice facilities at its Nijmegen campus in the Netherlands. Byonis regularly collaborates with leading global biotechnology and pharmaceutical companies, as well as with many academic research institutes. For more information visit www.byondis.com.